Maternal drug use is not new but over the last few decades, the number of mothers using drugs of addiction has escalated to epidemic levels. These drugs are both legal (e.g. prescription medication) and illegal (e.g. heroin) and all will cross the placental barrier into the developing infant. The most immediate and obvious consequence of intra-uterine drug exposure is newborn withdrawal or the Neonatal Abstinence Syndrome (NAS) which is now, with prompt recognition and treatment, an uncommon cause of neonatal death. Thousands (if not millions) of adults most likely would have had a history of passive drug exposure during gestation and the outcomes of these people are unknown. Most are physically healthy and do not need extra medical attention but the effects of prenatal drug exposure may be subtle and extensive. Drug-use disorders are accompanied by a myriad of other adverse problems, including poverty, mental and physical health problems and inadequate parenting ability that may compound the negative effects of drugs. Emerging data suggest that vulnerability to health and neurocognitive issues are pervasive and long-lasting as are lifestyle issues. This review will address current evidence in this area and highlight the knowledge gaps that must be addressed in order to optimise the outcomes for this vulnerable and marginalised but rapidly expanding population of adults.
Introduction
Women have used drugs of addiction for millennia. Until the late 1800s, many drugs, including cocaine and opioids, were freely available and considered medicinal and necessary for the maintenance of the mental and physical well-being of well-bred women. 1 Amphetamines and methamphetamine (ice) were used widely as nasal decongestants and 'nervous system' aids for housewives and sick children. 2 Cannabis had been used since preStone age to treat a variety of ailments, ranging from chronic pain to spasticity, cancer, seizure disorders, nausea, anorexia, hair loss and infection. 3 In Ancient Egypt, ground hemp was mixed with honey and inserted directly into the vagina to aid contractions and inhaled as a vapour to ease birth pains. Nowadays, certain contemporary societies, for example, Jamaica, even accept the use of drugs like cannabis (or ganja) as a useful and necessary therapy for 'female problems' especially those related to pregnancy and parenting, for example, loss of appetite, nausea, fatigue. 4 The impact of maternal drug use on their children is not without concern. For centuries, children were often treated with the same drugs used by their mothers. For example, heroin was aggressively marketed from as early as 1898 by the Bayer pharmaceutical company as a non-addictive and safe medication for childhood ailments, such as bronchitis, tuberculosis, infant colic and dry throat. 5, 6 In adults, it was approved by the American Medical Association in 1906 as a treatment for morphine addiction. Children were given medications containing cocaine for toothache (banned in the USA in 1920), chloroform for cold symptoms (banned by the US Food and Drug Administration (FDA) in 1976 for human consumption), barbiturates for nervous disorders and both barbiturates and cannabis for insomnia and seizures. 5 There are undoubtedly thousands (and probably millions) of children exposed to drugs of addiction throughout the years. The consequences of prenatal (and early childhood) exposure to these drugs on the child and later on the child as an adult are of great concern. This review will thus consolidate available literature on the impact of maternal drug use on their children as adults. Searches of publically available electronic databases (e.g. Pubmed, Embase and CINAHL) as well as a general internet search (e.g. Google) were employed.
Not all addictive drugs are illegal
It was only in the early 20th century that many drugs of dependency were legally restricted due to realisation of their addictive potential. Drug-trade was rapidly driven underground 2 but made minimal impact on human consumption of addictive drugs. The use of legally prescribed agents is rapidly increasing and is associated with serious impact on the unborn child. Between 2008-2013, at least 1 in 10 American mothers were prescribed an opioidcontaining medication during pregnancy, 6 a trend that was associated with 300% increase in the number of infants presenting with withdrawal or the Neonatal Abstinence Syndrome (NAS). 7 Advances in science also provided a means of producing drugs that were not plant based and therefore more easily accessible. Methamphetamines and other amphetamine-type substances, for example, can be easily manufactured in clandestine laboratories using common household agents 8 at ever increasing potencies. Any drug taken by the mother can affect the foetus and the newborn infant
Most molecules below 500 kDal will cross the placental barrier from the mother into the foetus. 10 Just as in adults, drugs of addiction cause foetal intoxication, tolerance and/or withdrawal, depending on the types of drugs taken by the mother. For example, amphetamines that are taken shortly before birth may result in an intoxicated, sleepy and obtunded infant 11 while heroin and opioids or other drugs, such as benzodiazepines, will lead to NAS. 12 
NAS -what is it?
The most obvious and immediate side-effect of maternal drug use is NAS. The term 'NAS' was coined in the 1970s by Loretta Finnegan and her colleagues 12 to describe a syndrome of withdrawal occurring in narcotic-exposed infants. NAS results from drug withdrawal after maternal transplacental drug transfer ceases abruptly at birth. Typically, it starts within a few hours or days after birth but its duration and intensity depend on many factors, including the types and doses of drugs taken by the mother, 13 genetic susceptibility, 14 type of feeding 15 and method of infant care. 16 Untreated NAS is devastating. Infants may fail to thrive, develop seizures or even die. 17 NAS can be protracted with subclinical symptoms lasting for months 18 and is well described in Western literature from as early as the 19th century, 17 accounting for massive healthcare consumption, most of which is met by public health funds. 7 
NAS is not the only problem
If promptly treated, NAS seldom causes death. 19 However, NAS is not the only problem faced by children of drug-using mothers. Many mothers with drug-using disorders use multiple drugs 20 and have poor lifestyle issues that worsen the outcomes for their children. For example, parents affected by drug-use disorders may be unable to parent adequately, with parenting styles ranging from being neglectful, to being over-authoritative and inappropriate, putting their children at risk of physical, emotional and sexual harm. 21 In Australia, more than 50% of methadone-maintained mothers were placed into foster care by age 5 22 and in a data linkage study, Uebel et al. showed that children with a post-birth diagnosis of NAS were 21 times more likely to be hospitalised during childhood for assaults, injuries and maltreatment 23 and three times more likely to die 24 before the age of 12 than other Australian children. This all adds up to great social vulnerability and chronic stress, which in turn, potentially impairs adequate development of adult working memory, general cognitive functioning, attention and executive function. 25 Can gestational chronic drug exposure itself lead to cognitive dysfunction?
All drugs of addiction, regardless of their eventual clinical effect, elicit the pleasurable sensations associated with drug use by modulating neurotransmitter levels and function. Repetitive stimulation of neurotransmitter neurons eventually results in neurotransmitter depletion, oxidative stress and finally, neuronal death. 26 Chronic drug users show evidence of brain volume loss, particularly within deep nuclear structures. 27 These deficits are associated with functional abnormalities that may persist for years even after abstinence. 28 Downregulation of neurotransmitter function is linked to neurocognitive impairment and dysfunction in both animals 29 and humans 30 and indeed, drug addiction is hypothesised to be the result of enduring changes to ventral striatal and prefrontal cortical circuits that receive input from midbrain dopaminergic neurons governing affective and cognitive functions. 31 Babies who are exposed to intra-uterine opioids have significantly smaller whole brain, basal ganglia and cerebellar volumes than other children but whether this is caused by drug exposure or other factors (e.g. poor nutrition, chronic stress) during gestation or whether these findings persist as the child grows into an adult, is as yet, unknown. 32 What are the drug-exposed children like as adults?
Determining long-term outcomes for drug-exposed babies beyond childhood is difficult because most of these children, apart from withdrawal or intoxication, are healthy. 12, 17 Few seldom need medical attention 20 and many may also have unstable home lives resulting in frequent shifts between multiple carers, homes and schools, 21 making them difficult to locate for any protracted time. Also, most mothers use multiple drugs, 19 have multiple environmental, psychiatric and lifestyle co-morbidities and stressors 33 that make isolating any specific long-term outcomes to a single drug, exceedingly difficult.
What do we know so far?
Neurodevelopment and cognitive function
The most enduring neurodevelopmental and cognitive outcome data have examined persons prenatally exposed to cannabis, the most commonly used illicit drug in the world. 34 The Ottawa Prenatal Prospective Study (OPPS) recruited a middle-class, low risk group of Caucasian babies born in Canada from 1978 and has since reported on outcomes to 22 years of age. 35 Although there were earlier concerns for behavioural problems (e.g. aggression 36 ), adults no longer displayed any evidence of major impairment in the second decade of life. However, subtle changes persisted. Prenatal cannabis-exposed adults (n = 16) performed similarly on cognitive testing (e.g. Visuospatial 2-Back, Go/NoGo, Letter 2-Back and Counting Stroop tasks) to nonexposed adults (n = 15) but functional magnetic resonance imaging demonstrated that their efforts were associated with significantly different brain blood flow responses, especially in the left posterior brain, suggesting persistence of prenatal cannabis effect even until adulthood. 35 Studies of other drugs, for example, opioids, are not so enduring and are contaminated by exposure to other drugs and adverse lifestyle issues. Nygaard et al. compared cognitive function in 45 youths between 17 and 21 years of age who were exposed in utero to heroin and multiple drugs, to 48 non-drug-exposed youths. As adults, the drug-exposed cohort had significantly worse cognitive and fine motor function but whether this was due to heroin-exposure was uncertain as most had been placed in foster care from as early as 1 year of age. 37 Certainly, the compounded factors of adverse environmental situations, such as unstable and chaotic home lives and poverty, add to poor outcomes with or without intra-uterine drug exposure. 38 
Risk to addiction
Addiction is a complex chronic psychiatric illness with a high relapse rate. The predisposition to addiction is intimately influenced by genetic and environmental factors. Compared with non-exposed children, the children of drug-using parents are more than twice as likely to develop an alcohol and/or drug use disorder themselves in adulthood. 39 For example, 53% of children of alcoholics develop alcohol or drug use disorders in adulthood 40 and also start using substances earlier and at faster rates. 39 Twin studies show that 48-58% of the variation in liability to alcoholism is genetically modulated 41 with certain genes (e.g. JUN, CEBPB, PRKCB, ENO2 or CEBPG) capable of predicting risk to heroin addiction with 85% accuracy in known drug users. 42 Gestational drug exposure may represent the first hit to a susceptible, developing neurological system. Prenatal cannabis, for example, may interfere with the endocannabinoid system, an important modulator and influence of neurodevelopment until adulthood. 43 Indeed, long-term studies of prenatal cannabis exposure show an increased risk of poor social outcomes, including criminal activity, lower education levels, having children without being married, unemployment 44 and psychiatric dysfunction. [44] [45] [46] Emotional, behavioural and social adjustment Emotional, behavioural and social adjustment is crucial for productive social functioning. Poor emotional and behavioural function is evident in children of substance users from early as 2-3 years of age 47 with increased rates of anxiety, depression, oppositional behaviour, conduct problems and aggressive behaviour as well as lower rates of self-esteem and social competence. [48] [49] [50] A range of adverse adult problem behaviours, such as externalising behaviours, impulsivity and attention problems, is particularly associated with gestational cocaine 51 and methadone. 52 In later life, offspring of heroin dependent parents have an 8-fold risk of depression, a 3-fold risk of attention disorders and a 16-fold risk of substance use disorders in young adulthood (average 17.9 years 53 ) but despite this, the exact relationship between prenatal drugs and future mental health issues in offspring remain unclear.
Resilience
Despite these problems, more than 50% of children of substance users are resilient to poor outcomes. 39 In the general population, certain behaviours predict resilience. For example, a survey of 19 303 middle to high school students from 82 Norwegian schools found that specific factors, such as the quality of parent-child relationships and absence of negative drug-related beliefs, close relationships with drug users, low delinquency rates, regular tobacco use and alcohol intoxication, predicted resilience to teenage cannabis use. 55 Behavioural resilience, defined as the lack of early (<14 years) substance use, risky sexual behaviour or delinquency, is also positively influenced by strict caregiver supervision, lower violence exposure and absence of intra-uterine tobacco exposure even in children exposed to prenatal drugs, such as cocaine. 56 There is ample evidence to show that programmes designed to enhance and support individual and family resilience have lasting effects, not only on drug use 57 but also on suicidal risk, 58 depression, anxiety, disruptive behaviours 58 and even intergenerational vulnerability to such adversities. 59 
Physical health
Even though most drug-exposed children are healthy as infants, up to 25% of them may not receive adequate healthcare within the first 2 years of life. 60 The impact of this neglect on long-term health is unknown. Similar findings to Uebel et al.'s Australian data 23, 24 were shown in a data linkage study of 55 369 children born in Finland in 2002. In this study, children of drug-using mothers were hospitalised more frequently for injuries and infection, and the risk of health problems was increased if the mother abused both alcohol and drugs rather than drugs alone, 61 suggesting that physical health problems may be an acquired issue rather than being a consequence of intra-uterine drug exposure.
Academic outcomes
School performance is one of the most important achievements of childhood. School failure leads to poor adult outcomes. Low education levels, cognitive deficits, deprived upbringing and delinquency are consistent childhood traits in prisoners, 62 the unemployed, 63 the poor 64 and in drug users. 65 Indeed, an individual's IQ at age 8-9 years consistently predicts future poor outcomes, including crime, substance use disorders, mental health, sexual adjustment (number of sexual partners, pregnancy) and lower educational achievement (school leaving qualifications, tertiary qualifications) and occupational status (unemployment, income 66 ). Conversely, higher intelligence is linked to better physical health at age 50, such as lower risk of diabetes and stroke. 67 To date, there is no study examining the relationship between intra-uterine drug exposure and adult academic achievement. At most, follow-up has been truncated at adolescence or even prior. There are consistent indications that prenatal drug exposure, for example, to marijuana, 44 cocaine 68 and opioids 69 compromises school performance and cognitive skills from as early as 8-9 years of age and until high school. Oei et al. used linkage data to examine the performance on Australian standardised curriculum based tests for 2234 children diagnosed with NAS as infants to the first year of high school. Compared to children without a diagnosis of NAS, mean test scores (range 0-1000) for children with NAS were significantly lower from as early as Grade 3. By Grade 7, or the first year of high school, the differences had increased. Children with NAS scored lower than other children in Grade 5 who were on average, 2 years younger, even after accounting for confounding factors, such as indigenous status, male gender and parental education. 69 Again, these studies cannot apply causality but suggest that cognitive support and educational intervention must be provided for any child known to be exposed to intra-uterine drugs to decrease the risk of poor school outcomes.
Criminal activity, involvement with the justice system and other deviant behaviours
The offspring of drug users have earlier and more frequent engagement in criminal activity. In 206 cases of serious child abuse or neglect in the juvenile court system of Boston, Murphy et al. found that 43% of cases had at least one parent with a substance use problem, with the proportion increasing to 50% when alleged substances included alcohol, cocaine and heroin. 70 Problems with criminal activity increased when there was concurrent school failure, truancy, suspension or expulsion and the need for drug and alcohol treatment. 71 A series of interviews with 70 substance abusers about their 188 children found that 80% had been arrested, 34% reported being treated for an emotional disorder and 17% were abusing drugs and alcohol. 71 What really happens to the adults?
Currently, the information we have do not, and cannot, definitively link intra-uterine drug exposure to adult adverse outcomes. Herranz et al. conducted a series of interviews with 30 heroin-exposed adults (mean age 22.3 years) with a postnatal diagnosis of NAS and found that adverse problems were common from early childhood. Of the original cohort of 151 children, five had died (four from acquired immune deficiency syndrome, one of unknown reasons) and 94 were not locatable. More than 50% of their mothers were HIV positive and 40% of mothers and 30% of fathers died after birth. Almost a quarter (23%) were adopted/fostered before childhood and >25% reported emotional and physical abuse. Attention deficit hyperactivity disorder was diagnosed in 20%, 76% smoked, five reported hazardous drinking, 87% had used cannabis at least once and almost half (47%) had used cocaine. Half undertook post-school studies but 37% were unemployed. More than half (57%) had received psychiatric treatment during childhood. 72 
Conclusion
This review highlights the concerns and lack of information about the long-term outcomes of adults with a history of intra-uterine drug exposure. Studies are confounded with the many problems associated with a drug-using lifestyle, including socio-economic, emotional and psychological adversities. However, the limited data available suggest that the impact of intra-uterine drug exposure, regardless of drug type, can be subtle but may be pervasive and detrimental to future adult outcomes. Whether these problems can transmit into future generations is yet to be determined. Considering the rapidly escalating magnitude of perinatal drug use, efforts must be urgently made to determine these consequences so that children can be provided with opportunities to mitigate future vulnerability not only for themselves as adults, but for future generations of children.
